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The Delta:Notch signaling pathway regulates numerous
aspects of differentiation, morphogenesis and cell func-
tion, during embryogenesis and throughout adult life.
More recently, Delta-like 4 (Dll4) has been shown to
regulate adult neo-vascularization (angiogenesis). Conse-
quently, therapeutic strategies to target Dll4 have been
put forward for the treatment of different cancers. In
the present study, we describe for the first time that
Dll4 blockade affects the bone marrow (BM) microen-
vironment, by perturbing the BM vascular niche. Anti-
Dll4 treatment administered 1 day after myeloablation
increased the BM vascular content (CD31
+ cells), pro-
moted megakaryopoiesis and promoted hematopoietic
(Sca1
+) and endothelial progenitor (Flk1
+CXCR4
+) cell
mobilization to the peripheral blood (PB). Moreover,
anti-Dll4 treatment increased BM myeloid content, and
induced mobilization of B (B220
hiCD19
lo)a n d
T (CD3
+NK1.1
-) lymphocytes to the PB. Taken together,
we show that Dll4 blockade affects the BM vascular
niche, and as such affects hematopoietic cell differentia-
tion and mobilization.
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